Roc Pharmaceuticals is the first company focusing on developing pharmaceuticals to cure various diseases resulted from glycosylation defects of dystroglycan such as muscular dystrophies and metastatic cancers. We are the leader in the field supported by NIH and MDA. There are millions of patients suffering from these diseases but with effective treatment. The market (>$1 billions per year) is huge and there is no competitor yet.